- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
KOL report: Nu.Q® NETs and sepsis
- Share
- Tweet
- Share on Facebook
- Share
Report from world leaders in sepsis care KOL meeting hosted by Volition in September 2023 to discuss how Nu.Q® NETs could best be used in clinical practice.
The panel discussed how Nu.Q® NETs could be used to enhance the management and outcome of sepsis patients and its potential application in early diagnosis, treatment guidance, treatment monitoring, and personalized medicine.
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields